White Diamond Research says Pulse Biosciences (PLSE)’ Nano-Pulse Stimulation technology “has a long history of commercial failures which contradict the company’s sky-high valuation of $1B+.” In a research report posted on its website, White Diamond argues Pulse’s new application in benign thyroids will be “another dead end.” The company’s “history of failure will likely continue,” the firm contends.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLSE: